Production (Stage)
Elite Pharmaceuticals, Inc.
ELTP
$0.517
-$0.0022-0.42%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.00M | 14.36M | 18.88M | 18.80M | 17.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.00M | 14.36M | 18.88M | 18.80M | 17.95M |
| Cost of Revenue | 14.70M | 8.24M | 10.68M | 10.33M | 9.83M |
| Gross Profit | 17.30M | 6.12M | 8.20M | 8.47M | 8.12M |
| SG&A Expenses | 2.09M | 2.80M | 2.33M | 2.02M | 2.29M |
| Depreciation & Amortization | 409.90K | 432.50K | 420.30K | 425.70K | 380.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.24M | 13.27M | 15.40M | 14.94M | 14.22M |
| Operating Income | 12.76M | 1.10M | 3.48M | 3.86M | 3.73M |
| Income Before Tax | 19.27M | -10.65M | -9.52M | 847.80K | 1.99M |
| Income Tax Expenses | 2.27M | 239.20K | 1.52M | 232.00K | -1.33M |
| Earnings from Continuing Operations | 17.00M | -10.89M | -11.04M | 615.80K | 3.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.00M | -10.89M | -11.04M | 615.80K | 3.33M |
| EBIT | 12.76M | 1.10M | 3.48M | 3.86M | 3.73M |
| EBITDA | 13.17M | 1.53M | 3.91M | 4.29M | 4.10M |
| EPS Basic | 0.02 | -0.01 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | 0.02 | -0.01 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.07B | 1.07B | 1.07B | 1.07B | 1.02B |
| Average Diluted Shares Outstanding | 1.07B | 1.07B | 1.07B | 1.08B | 1.03B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |